Why Revelation Biosciences (REVB) Shares Are Surging Today - Revelation Biosciences (NASDAQ:REVB)

Revelation Biosciences Inc REVB announced topline data for its Phase 1b CLEAR study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.
The study met the primary endpoint evaluating the effects of REVTx-99b versus placebo on safety and tolerability.
Exploratory endpoints for efficacy were not met, including no reduction in allergy symptoms and increase in peak nasal inspiratory flow versus placebo.
Revelation management plans to evaluate the future development of this and other ongoing programs.
REVTx-99b is a proprietary intranasal formulation in development for managing allergic rhinitis symptoms, including chronic nasal congestion.
Phase 2b viral challenge study data announced in March showed that REVTx-99a did not meet its primary endpoint, the area under the curve of viral load by quantitative RT-PCR from nasopharyngeal swabs.
Price Action: REVB shares are up 78.9% at $1.15 during the premarket session on the last check Monday.

Revelation Biosciences Surges After Encouraging Data From Allergic Rhinitis Study